Navigation Links
Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
Date:2/11/2009

COLUMBIA, S.C., Feb. 11 /PRNewswire/ -- Welvista is pleased to announce it has reached an agreement with Takeda to dispense a selection of the company's medications to the uninsured through Welvista's no-cost prescription medication program. With the addition of six Takeda products, Welvista now has 213 drugs on its formulary for the uninsured. Including Takeda, Welvista now partners with 12 pharmaceutical companies, making it the largest mail-order pharmacy for the uninsured in the country.

Welvista provides an innovative prescription drug program for residents in South Carolina and Texas who fall below 200 percent of the federal poverty level and are without health insurance coverage. The William E. Murray pharmacy, located at Welvista's headquarters off Forest Drive in Columbia, dispensed more than $34.5 million dollars in prescription medications in 2008 to Welvista's patients to treat diabetes, hypertension, mental illness and more.

Welvista also provides oral healthcare services for the children of limited income families in South Carolina through Smiles for a Lifetime, with centers in Allendale County, Dillon II, and Clarendon I and II school districts, and Charleston.

"We are excited to have Takeda as our newest pharmaceutical partner. We couldn't exist without our generous partners," says Welvista CEO Ken Trogdon. "We are committed to improving health and wellness for the uninsured. Our model has proven its viability and we will continue to add prescription drugs that we know our patients need."

About Welvista

Welvista is an innovative model of non-governmental healthcare intervention serving thousands of patients in SC and Texas. This healthcare network provides medications at no cost to the uninsured who do not qualify for Medicaid, Medicare or VA insurance and those who cannot afford to pay for insurance coverage on their own. Welvista also operates Smiles, five pediatric dental care centers caring for approximately 3,200 children from limited income families who would not otherwise have access to oral healthcare. With the addition of Takeda, Welvista now partners with 12 pharmaceutical companies that donate prescription drugs to approved patients. To learn more about the organization, visit www.welvista.org.

About Takeda Pharmaceuticals North America, Inc.

Based in Deerfield, Illinois, Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, oncology, gastroenterology, neurology, rheumatology and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about these Takeda companies, visit www.tpna.com.


'/>"/>
SOURCE Welvista
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
2. ActivCore LLC Announces Strategic Partnership with Wellness in Motion
3. Sensiotec Announces FDA 510(k) Class II Clearance for the Worlds First UWB Healthcare Unbound, Wireless, Non-Contact, Vital Signs and Movement Monitor
4. TheWrap.Com Announces MPTF is Responding to Media Investigation
5. Hillenbrand Announces Dividend of $0.185 Per Share
6. China-Biotics, Inc. Announces Conference Call to Discuss Third Quarter 2009 Financial Results
7. HCA Announces Offering of $300 Million Senior Secured Second Lien Notes
8. Triple-S Management Corporation Announces Delay in Reporting Fourth-Quarter And Year-End Results
9. The Network Journal Announces it's 2009 List of "25 Influential Black Women in Business"
10. Prison Health Services, Inc. Announces Contract for Prisoner Health Care Services With the State of Michigan Department of Corrections
11. NBTY Announces Preliminary Unaudited Net Sales Results for January 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... San Fernando Valley, CA (PRWEB) , ... December 07, 2016 , ... ... Sculptra can be used in several ways to restore a more youthful appearance to ... doctors , now offer Sculptra, along with a variety of other treatments, to rejuvenate ...
(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes ... and around the nation. What do they have in common? All have been affected ... compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... financial consultation services from offices located in South Lyon, Dewitt, Williamston, East Lansing, ... a basketball coach who needs treatment for a brain tumor. , Jason Bauer ...
(Date:12/7/2016)... , ... December 07, 2016 , ... One of two ... of the securement tape is painful for her. "This is why the co-inventor and ... heads," she said. , They then created a prototype of the patent-pending AV-AIR, a ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... ... new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... The study was published in the prestigious Journal of Veterinary Science & Medical ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... 7, 2016 Boehringer Ingelheim today announced ... with unresectable malignant pleural mesothelioma (MPM) met its ... presented at the 17 th IASLC World ... , showed nintedanib plus pemetrexed/cisplatin demonstrated a ... with a significantly improved PFS (9.4 vs 5.7 ...
(Date:12/7/2016)... , December 7, 2016 Today, Stock-Callers.com ... (NASDAQ: JAZZ ), Anthera Pharmaceuticals Inc. (NASDAQ: ... ), and AveXis Inc. (NASDAQ: AVXS ). From ... fell roughly 37% to reach a level equal to what ... down by approximately 14% for the year, it has still ...
Breaking Medicine Technology: